SCHEMBL3667385

SCHEMBL3667385

Nc1cncc(Cl)c1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 5/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
MAPT P10636 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
KDM6B O15054 1/20 0.42
KDM4A O75164 1/20 0.42
THRB P10828 1/20 0.42
KDM4D Q6B0I6 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HCAR2 Q8TDS4 2/20 0.39
LMNA P02545 1/20 0.39
DDO Q99489 1/20 0.39
GAA P10253 2/20 0.39
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111872 0.84 HCAR2 (0.46) ALDH1A1KDM4EKMT2AMEN1MAPT
Hydrochloric Acid SCHEMBL5204506 0.82 HCAR2 (0.45) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL5760445 0.82 HCAR2 (0.45) ALDH1A1KDM4EKMT2AMEN1MAPT
Formaldehyde SCHEMBL28038712 0.80 HCAR2 (0.43) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL535478 0.77 ALDH1A1 (0.49) ALDH1A1KDM4EKMT2AMEN1LMNA
SCHEMBL1245001 0.77 KDM4E (0.53) ALDH1A1KDM4EKMT2AMEN1MAPT
Nitrous Acid SCHEMBL28928125 0.77 HCAR2 (0.41) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL24808960 0.75 KDM4E (0.42) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL18171007 0.75 KDM4E (0.43) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL21825962 0.75 HDAC3 (0.41) ALDH1A1KDM4EMAPTHCAR2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2057156-B1 2-METHYLMORPHOLINE PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS KUDOS PHARM LTD (GB) 2017-02-01 EP disclosed
EP-2262504-A1 COMBINATION THERAPY 238 AstraZeneca AB (SE) 2010-12-22 EP disclosed
WO-2009104019-A1 COMBINATION THERAPY 238 ASTRAZENECA AB (SE) 2009-08-27 WO disclosed
EP-2057156-A1 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS Kudos Pharmaceuticals Limited (GB) 2009-05-13 EP disclosed
US-20090099174-A1 COMBINATION 059 ASTRAZENECA AB (SE) 2009-04-16 US disclosed
WO-2008023161-A1 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099174-A1 COMBINATION 059 MTOR, RICTOR, MAPK9 ALDH1A1 3754/4885KDM4E 245/4885KMT2A 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.